3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Carcinoma, Intraductal, Noninfiltrating
2
Smoldering Multiple Myeloma
1
Polyps
1
Peripheral Nervous System Diseases
1
Monoclonal Gammopathy of Undetermined Significance
1
Malnutrition
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Dyspareunia
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Breast Neoplasms, Male
1
Breast Carcinoma In Situ
1
Interventions
Glutamine
2
sagopilone
1
nicotinamide-beta-riboside
1
allantoicase
1
Vitamin D
1
Vitamin B 6
1
Vitamin B 12
1
Taxoids
1
Tadalafil
1
Sirolimus
1
Prednisolone
1
Paclitaxel
1
Minocycline
1
Metformin
1
Losartan
1
Hydroxychloroquine
1
G(M1) Ganglioside
1
Fatty Acids, Omega-3
1
Exercise
1
Everolimus
1
Etoricoxib
1
Ethosuximide
1
Epoetin Alfa
1
Dietary Supplements
1
Dexamethasone
1
Cryotherapy
1
Bortezomib
1
BID protein, human
1
Acupuncture Therapy
1
Acetylcysteine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Peripheral Nervous System Diseases
×
Fatty Acids, Omega-3
×
Clear all
NCT02795572
2019-07-05
CIPN
AHS Cancer Control Alberta
Phase 2
Terminated
13 enrolled